Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Boston Scientific Corp.

www.bostonscientific.com

Latest From Boston Scientific Corp.

Market Intel: Let's Talk About It — The Rising Tide Of 'Femtech' Companies

Femtech, which describes digital technologies that aim to improve women's health, is expected to reach $50bn in market size by 2025, according to Frost & Sullivan. Reproductive health and menstrual health trackers are two of the fastest-growing sectors in femtech. We've highlighted some of the biggest players in both segments, their innovative business models, plans and also looked at barriers such as privacy issues, accuracy of mobile applications and funding challenges.

Market Intelligence Commercial

Medtechs Ready To Take Creative Approach To Deal-Making With An Eye On Start-Ups

Ground-breaking M&A deals were largely absent from medtech industry schedules in 2018 – Boston’s BTG deal aside – but that does not mean consolidation of the medtech industry is slowing down. M&A deal numbers have been steady of late, even if aggregate deal value has declined in recent years. Digital transformation is a catalyst for a growing number of sector-transforming transactions.

Digital Health Deals

SCAI, Manufacturers Defend Peripheral Paclitaxel Devices Against Doubts

The Society for Cardiovascular Angiography and Interventions’ Vascular Disease Council says the recent meta-analysis finding a higher long-term mortality risk with paclitaxel-eluting peripheral devices can only be viewed as hypothesis-generating. The long-term risks of these devices should be investigated with patient-level data, SCAI argues. Several clinical data presentations at the recent LINC meeting in Leipzig showed comparable mortality rates with paclitaxel-eluting devices as comparable non-drug-eluting devices.

Clinical Trials FDA

Starts & Stops: Boston Scientific Launches New Lotus TAVR Trial, Medtronic Starts Study Of SynchroMed II Pain Pump

Starts & Stops compiles all the clinical trial announcements, initiations, completions and suspensions tracked by MedDeviceTracker. This edition covers trial announcements from Jan. 7 through Jan. 27, including announcements from Medtronic, QT Vascular, Boston Scientific, and Shockwave.

Starts & Stops Tracking Trials
See All

Company Information

Advertisement
Advertisement
UsernamePublicRestriction

Register